Article
FDA's Pazdur Outlines How Oncology Center of Excellence Will Promote Collaboration in AJMC®'s Evidence-Based Oncology
The National Cancer Moonshot initiative called for tearing down the silos that prevent researchers from sharing information. FDA’s Richard Pazdur, MD, is doing just that-through the new Oncology Center of Excellence. Pazdur shares how the center will work in a special issue of Evidence-Based Oncology, publication of The American Journal of Managed Care.®
FOR IMMEDIATE RELEASEMay 18, 2017
CRANBURY, N.J.—During his 18 years at FDA, Richard Pazdur, MD, has worked to balance the needs of patients anxious for new cancer cures with the agency’s standards that protect them from harm. In January, Pazdur took on a new role—director of the new Oncology Center of Excellence (OCE), which was borne of the National Cancer Moonshot’s call for greater collaboration among those charged with speeding the arrival of new cancer-fighting products.
Pazdur outlines how OCE will function—and how it bring a stronger patient voice to FDA’s decisions—in a special issue of Evidence-Based Oncology,™ (EBO™); the issue features coverage from the spring 2017 Oncology Stakeholders’ Summit, which focused on regulatory issues.
“This new center leverages the combined skills of regulatory scientists and reviewers with oncology clinical expertise across the FDA, emulating the multidisciplinary organizational model of academia and cancer care centers and building on the integrative approach to medical product development that the agency’s broader oncology community has embraced over the past decade,” Pazdur writes.
Since 2005, when he became director of the Office of Hematology and Oncology Products (OHOP) within FDA, Pazdur has overseen the arrival of faster pathways to approval, which tracked the rise of new treatment methods, including immunotherapy. As he explains, OCE builds on that record but with some key additions. “An important aim of the OCE is to facilitate incorporation of the patient view into regulatory decision-making,” he writes.
A key feature of the OCE calls for new submissions to head to a clinical review team that draws from three medical product centers. The team will make recommendations, which will head to Pazdur for review and sign-off. Other aspects of FDA review remain with their traditional centers, he explains. The OCE will embrace new trial designs, with the goal of making research simpler and requiring fewer data points.
“These initiatives will allow us to expedite drug development and approval of truly novel agents that will have a major impact on our patients, while allowing us to make thoughtful decisions regarding the risk-benefit of oncology drugs,” Pazdur writes.
Pazdur remains the acting director of OHOP while taking on his new role.
About The American Journal of Managed Care®:
The American Journal of Managed Care® (AJMC®) is a peer-reviewed, MEDLINE-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care® and two evidence-based series, Evidence-Based Oncology™ and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Dr. Jeff Prescott at (609) 716-7777, x331.
CONTACTS:
AJMC® Media:
Theresa Burek
or
Surabhi Verma
Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL
